Healthy Participant Study: Clinical Trials

5 trials for Healthy Participant Study, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 recruiting. 3 Phase 1, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Recruiting 1
Not applicable2Completed 1, Recruiting 1

Follow Healthy Participant Study: new trials by email Literature Review of Healthy Participant Study trials Research Report on Healthy Participant Study

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Slowly Digestible Carbohydrates for GLP-1 Secretion
Maltodextrin (Placebo), Raw Corn Starch - Blood Glucose, GLP-1
Not applicableRecruitingPurdue University192026-05-012026-05-07
A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
QRL-101, Placebo - Healthy Participant Study
Phase 1CompletedQurAlis Corporation482026-02-022026-10-06
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
BEAM-103, Placebo Comparator - Healthy Subjects, Healthy Participant Study
Phase 1RecruitingBeam Therapeutics Inc.302025-10-272025-12-26
RE104 Radiolabeled Mass Balance (hAME) Study
2-[14C]-RE104 for Injection - Healthy Participant Study
Phase 1CompletedReunion Neuroscience Inc82025-08-192025-11-20
MRI-tDCS Criticism Study
tDCS - Healthy Participant Study
Not applicableCompletedUniversitair Ziekenhuis Brussel472013-07-092026-02-12

Interventions

Injections (1)  ·  Starch (1)  ·  Transcranial Direct Current Stimulation (1)  ·  maltodextrin (1)

Sponsors

Beam Therapeutics Inc. (1)  ·  Purdue University (1)  ·  QurAlis Corporation (1)  ·  Reunion Neuroscience Inc (1)  ·  Universitair Ziekenhuis Brussel (1)

Countries

United States (2)  ·  Belgium (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Mark Pollack, Chief Medical Officer (1)

NIH funding

2025 (1)